Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
Anne Kristine Anstensrud, Sindre Woxholt, Kapil Sharma, Kaspar Broch, Bjørn Bendz, Svend Aakhus, Thor Ueland, Brage H Amundsen, Jan Kristian Damås, Einar Hopp, Ola Kleveland, Knut Haakon Stensæth, Anders Opdahl, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Rune Wiseth, Pål Aukrust, Lars Gullestad, Anne Kristine Anstensrud, Sindre Woxholt, Kapil Sharma, Kaspar Broch, Bjørn Bendz, Svend Aakhus, Thor Ueland, Brage H Amundsen, Jan Kristian Damås, Einar Hopp, Ola Kleveland, Knut Haakon Stensæth, Anders Opdahl, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Rune Wiseth, Pål Aukrust, Lars Gullestad
Abstract
Introduction: Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation MI (NSTEMI). Experimental studies suggest that IL-6 inhibition can limit infarct size through anti-inflammatory mechanisms, but this has not been tested in clinical studies. With the ASSessing the effect of Anti-IL-6 treatment in MI (ASSAIL-MI) trial, we aim to examine whether a single administration of the IL-6 receptor antagonist tocilizumab can increase myocardial salvage in patients with acute ST-elevation MI (STEMI).
Methods and analysis: The ASSAIL-MI trial is a randomised, double blind, placebo-controlled trial, conducted at three high-volume percutaneous coronary intervention (PCI) centres in Norway. 200 patients with first-time STEMI presenting within 6 hours of the onset of chest pain will be randomised to receive tocilizumab or matching placebo prior to PCI. The patients are followed-up for 6 months. The primary endpoint is the myocardial salvage index measured by cardiac MRI (CMR) 3-7 days after the intervention. Secondary endpoints include final infarct size measured by CMR and plasma markers of myocardial necrosis. Efficacy and safety assessments during follow-up include blood sampling, echocardiography and CMR.
Ethics and dissemination: Based on previous experience the study is considered feasible and safe. If tocilizumab increases myocardial salvage, further endpoint-driven multicentre trials may be initiated. The ASSAIL-MI trial has the potential to change clinical practice in patients with STEMI.
Registration: Clinicaltrials.gov, identifier NCT03004703.
Keywords: MRI; Myocardial Ischaemia and Infarction (IHD); coronary artery disease; cytokines; inflammation.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Timmis A, Townsend N, Gale C, et al. . European Society of cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018;39:508–79. 10.1093/eurheartj/ehx628
- Benjamin EJ, Virani SS, Callaway CW, et al. . Heart disease and stroke Statistics-2018 update: a report from the American heart association. Circulation 2018;137:e67–492. 10.1161/CIR.0000000000000558
- Kleveland O, Kunszt G, Bratlie M, et al. . Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J 2016;37:2406–13. 10.1093/eurheartj/ehw171
- Libby P, Pasterkamp G, Crea F, et al. . Reassessing the mechanisms of acute coronary syndromes. Circ Res 2019;124:150–60. 10.1161/CIRCRESAHA.118.311098
- Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76:1713–9. 10.1172/JCI112160
- Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121–35. 10.1056/NEJMra071667
- Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–50. 10.1161/01.CIR.91.11.2844
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–95. 10.1056/NEJMra043430
- Ridker PM, Everett BM, Thuren T, et al. . Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31. 10.1056/NEJMoa1707914
- Morton AC, Rothman AMK, Greenwood JP, et al. . The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur Heart J 2015;36:377–84. 10.1093/eurheartj/ehu272
- Van Tassell BW, Lipinski MJ, Appleton D, et al. . Rationale and design of the Virginia Commonwealth University-Anakinra remodeling Trial-3 (VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study. Clin Cardiol 2018;41:1004–8. 10.1002/clc.22988
- Granger CB, Mahaffey KW, Weaver WD, et al. . Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the complement inhibition in myocardial infarction treated with angioplasty (CoMMA) trial. Circulation 2003;108:1184–90. 10.1161/01.CIR.0000087447.12918.85
- Cung T-T, Morel O, Cayla G, et al. . Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015;373:1021–31. 10.1056/NEJMoa1505489
- Mahaffey KW, Granger CB, Nicolau JC, et al. . Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the complement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176–83. 10.1161/01.CIR.0000087404.53661.F8
- Deftereos S, Giannopoulos G, Angelidis C, et al. . Anti-Inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation 2015;132:1395–403. 10.1161/CIRCULATIONAHA.115.017611
- Tardif J-C, Tanguay J-F, Wright SR, et al. . Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol 2013;61:2048–55. 10.1016/j.jacc.2013.03.003
- O'Donoghue ML, Glaser R, Cavender MA, et al. . Effect of Losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 2016;315:1591–9. 10.1001/jama.2016.3609
- Biasillo G, Leo M, Della Bona R, et al. . Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 2010;5:225–33. 10.1007/s11739-010-0361-1
- Kinlay S, Schwartz GG, Olsson AG, et al. . High-Dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560–6. 10.1161/
- Hou T, Tieu BC, Ray S, et al. . Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev 2008;4:179–92. 10.2174/157340308785160570
- Huang M, Yang D, Xiang M, et al. . Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction. Heart Fail Rev 2015;20:25–38. 10.1007/s10741-014-9431-1
- Fontes JA, Rose NR, Čiháková D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine 2015;74:62–8. 10.1016/j.cyto.2014.12.024
- Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001;6:95–103. 10.1023/A:1011401825680
- Kobara M, Noda K, Kitamura M, et al. . Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res 2010;87:424–30. 10.1093/cvr/cvq078
- Ritschel VN, Seljeflot I, Arnesen H, et al. . Circulating levels of IL-6 receptor and gp130 and long-term clinical outcomes in ST-elevation myocardial infarction. J Am Heart Assoc 2016;5. doi:10.1161/JAHA.115.003014
- Ridker PM, Libby P, MacFadyen JG, et al. . Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Eur Heart J 2018;39:3499–507. 10.1093/eurheartj/ehy310
- Kleveland O, Ueland T, Kunszt G, et al. . Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. Int J Cardiol 2018;271:1–7. 10.1016/j.ijcard.2018.04.136
- Naruko T, Ueda M, Haze K, et al. . Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106:2894–900. 10.1161/01.CIR.0000042674.89762.20
- Ueland T, Kleveland O, Michelsen AE, et al. . Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. Int J Cardiol 2019;274:348–50. 10.1016/j.ijcard.2018.06.093
- Eitel I, de Waha S, Wöhrle J, et al. . Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014;64:1217–26. 10.1016/j.jacc.2014.06.1194
- Erlinge D, Götberg M, Lang I, et al. . Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 2014;63:1857–65. 10.1016/j.jacc.2013.12.027
- Atar D, Arheden H, Berdeaux A, et al. . Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J 2015;36:112–9. 10.1093/eurheartj/ehu331
- Ibanez B, Macaya C, Sánchez-Brunete V, et al. . Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 2013;128:1495–503. 10.1161/CIRCULATIONAHA.113.003653
- Eitel I, Stiermaier T, Rommel KP, et al. . Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA conditioning trial. Eur Heart J 2015;36:3049–57. 10.1093/eurheartj/ehv463
- Regenfus M, Schlundt C, Krähner R, et al. . Six-Year prognostic value of microvascular obstruction after reperfused ST-elevation myocardial infarction as assessed by contrast-enhanced cardiovascular magnetic resonance. Am J Cardiol 2015;116:1022–7. 10.1016/j.amjcard.2015.06.034
- Lunde K, Solheim S, Aakhus S, et al. . Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199–209. 10.1056/NEJMoa055706
- Gibbons RJ, Valeti US, Araoz PA, et al. . The quantification of infarct size. J Am Coll Cardiol 2004;44:1533–42. 10.1016/j.jacc.2004.06.071
- Engblom H, Heiberg E, Erlinge D, et al. . Sample size in clinical cardioprotection trials using myocardial salvage index, infarct size, or biochemical markers as endpoint. J Am Heart Assoc 2016;5:e002708 10.1161/JAHA.115.002708
Source: PubMed